Literature DB >> 18710805

Synthesis and anti-CVB 3 evaluation of substituted 5-nitro-2-phenoxybenzonitriles.

Gerhard Pürstinger1, Armando M De Palma, Günther Zimmerhofer, Simone Huber, Sophie Ladurner, Johan Neyts.   

Abstract

The synthesis and SAR of a series of 60 substituted 2-phenoxy-5-nitrobenzonitriles (analogues of MDL-860) as inhibitors of enterovirus replication (in particular of coxsackievirus B3 (CVB 3)) are reported. Several of the analogues inhibited CVB 3 and other enteroviruses at low-micromolar concentrations.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18710805     DOI： 10.1016/j.bmcl.2008.07.099

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  3 in total

1.  Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.

Authors:  Adelina Stoyanova; Ivanka Nikolova; Gerhard Pürstinger; Georgi Dobrikov; Vladimir Dimitrov; Stefan Philipov; Angel S Galabov
Journal:  Antivir Chem Chemother       Date:  2016-11-04

2.  Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase.

Authors:  William L Jorgensen; Mariela Bollini; Vinay V Thakur; Robert A Domaoal; Krasimir A Spasov; Karen S Anderson
Journal:  J Am Chem Soc       Date:  2011-09-09       Impact factor: 15.419

3.  The RNA template channel of the RNA-dependent RNA polymerase as a target for development of antiviral therapy of multiple genera within a virus family.

Authors:  Lonneke van der Linden; Laia Vives-Adrián; Barbara Selisko; Cristina Ferrer-Orta; Xinran Liu; Kjerstin Lanke; Rachel Ulferts; Armando M De Palma; Federica Tanchis; Nesya Goris; David Lefebvre; Kris De Clercq; Pieter Leyssen; Céline Lacroix; Gerhard Pürstinger; Bruno Coutard; Bruno Canard; David D Boehr; Jamie J Arnold; Craig E Cameron; Nuria Verdaguer; Johan Neyts; Frank J M van Kuppeveld
Journal:  PLoS Pathog       Date:  2015-03-23       Impact factor: 6.823
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.